Related Experiment Videos

Evolving mechanisms of action of beta blockers: focus on nebivolol

R Preston Mason1, Thomas D Giles, James R Sowers

  • 1Cardiovascular Division, Department of Medicine Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA. rpmason@elucidaresearch.com

Journal of Cardiovascular Pharmacology
|June 17, 2009
PubMed

Insights

Beta blockers treat various conditions, but their mechanisms vary. Newer agents like nebivolol offer unique vasodilation, differing from older beta-blockers.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Beta blockers are crucial for cardiovascular and noncardiovascular diseases.
  • Their precise mechanisms of action are not fully elucidated and vary among agents.
  • Chronic adrenergic activity in heart failure leads to receptor desensitization and myocyte damage.

Purpose of the Study:

  • To review the class of beta-blocking agents.
  • To evaluate the differences in their pharmacodynamic and pharmacokinetic properties.
  • To understand the basis for clinical use variations among beta-blockers.

Main Methods:

  • Review of existing literature on beta-blocker pharmacology and clinical use.
  • Comparison of older versus newer generation beta-blockers.
  • Analysis of receptor affinity, selectivity, and ancillary properties.

Main Results:

  • Beta-blockers reduce heart rate and myocardial workload, potentially reversing cardiac remodeling.
  • Differences exist in selectivity (nonselective, beta1-selective) and partial agonist activity.
  • Third-generation beta-blockers, like nebivolol, possess nitric oxide-mediated vasodilation, distinguishing their hemodynamic profiles.

Conclusions:

  • The diverse properties of beta-blockers necessitate understanding their specific mechanisms for optimal clinical application.
  • Nebivolol's unique vasodilatory action sets it apart from traditional beta-blockers.
  • Further research into beta-blocker mechanisms can refine therapeutic strategies.

Related Concept Videos

Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...